A detailed history of Mc Clarren Financial Advisors, Inc. transactions in Biogen Inc. stock. As of the latest transaction made, Mc Clarren Financial Advisors, Inc. holds 2 shares of BIIB stock, worth $347. This represents 0.0% of its overall portfolio holdings.

Number of Shares
2
Previous 231 99.13%
Holding current value
$347
Previous $0 NaN%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 18, 2024

SELL
$189.07 - $236.8 $43,297 - $54,227
-229 Reduced 99.13%
2 $0
Q2 2024

Jul 26, 2024

BUY
$190.52 - $236.72 $43,629 - $54,208
229 Added 11450.0%
231 $0
Q1 2024

Jul 26, 2024

SELL
$212.02 - $267.71 $45,372 - $57,289
-214 Reduced 99.07%
2 $1,000
Q1 2024

May 03, 2024

BUY
$212.02 - $267.71 $45,372 - $57,289
214 Added 10700.0%
216 $1,000
Q4 2022

Jan 30, 2023

BUY
$252.44 - $306.72 $504 - $613
2 New
2 $0

Others Institutions Holding BIIB

About BIOGEN INC.


  • Ticker BIIB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 144,000,992
  • Market Cap $25B
  • Description
  • Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...
More about BIIB
Track This Portfolio

Track Mc Clarren Financial Advisors, Inc. Portfolio

Follow Mc Clarren Financial Advisors, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Mc Clarren Financial Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Mc Clarren Financial Advisors, Inc. with notifications on news.